A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Authors:
- Tracy R Daniels-WellsTDTracy R Daniels-Wells
- Gustavo HelgueraGHGustavo Helguera
- Richard K LeuchterRLRichard K Leuchter
- Rafaela QuinteroRQRafaela Quintero
- Maggie KozmanMKMaggie Kozman
- José A RodríguezJRJosé A Rodríguez
- Elizabeth Ortiz-SánchezEOElizabeth Ortiz-Sánchez
- Otoniel Martínez-MazaOMOtoniel Martínez-Maza
- Birgit C SchultesBSBirgit C Schultes
- Christopher F NicodemusCNChristopher F Nicodemus
- Manuel L PenichetManuel L Penichet
Open Access
- 17 April 2013
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
Abstract
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.Keywords
This publication has 70 references indexed in Scilit:
- Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cellsCancer Immunology, Immunotherapy, 2011
- Immunotherapy in prostate cancer: Emerging strategies against a formidable foeVaccine, 2011
- Targeting Continued Androgen Receptor Signaling in Prostate CancerClinical Cancer Research, 2011
- Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatmentsOncoTargets and Therapy, 2011
- Is there an optimal management for localized prostate cancer?Clinical Interventions in Aging, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphomaBlood, 2010
- Antitumor IgE Adjuvanticity: Key Role of FcεRIThe Journal of Immunology, 2009
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- AllergoOncology: the role of IgE‐mediated allergy in cancerAllergy, 2008